Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 60.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | -58.00K | -58.00K | -52.00K | -519.00K | -395.00K |
EBITDA | -23.08M | -13.64M | -34.19M | -7.64M | -35.30M | -27.14M |
Net Income | -20.87M | -13.70M | -34.36M | -35.60M | -35.82M | -27.53M |
Balance Sheet | ||||||
Total Assets | 19.08M | 19.79M | 12.19M | 39.67M | 69.09M | 101.79M |
Cash, Cash Equivalents and Short-Term Investments | 17.96M | 18.67M | 11.24M | 1.33M | 63.67M | 95.03M |
Total Debt | 0.00 | 0.00 | 0.00 | 5.36M | 0.00 | 0.00 |
Total Liabilities | 12.98M | 5.38M | 4.03M | 3.70M | 4.07M | 7.01M |
Stockholders Equity | 6.10M | 14.41M | 8.16M | -9.23M | 65.02M | 94.79M |
Cash Flow | ||||||
Free Cash Flow | -32.72M | -21.15M | -25.81M | -25.13M | -31.99M | -33.09M |
Operating Cash Flow | -32.69M | -21.15M | -25.73M | -22.88M | -31.50M | -32.06M |
Investing Cash Flow | 2.47M | -4.42M | 8.88M | 26.96M | 10.75M | -42.56M |
Financing Cash Flow | 19.58M | 27.97M | 20.90M | -139.00K | 695.00K | 92.17M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | 99.55M | -2.60 | -38.74% | ― | 1071.91% | -27.61% | |
51 Neutral | 87.23M | -3.11 | -127.97% | ― | -9.61% | 20.36% | |
44 Neutral | 16.76M | -0.62 | -146.48% | ― | 68.67% | 85.44% | |
39 Underperform | $45.13M | ― | -209.36% | ― | ― | 15.19% | |
36 Underperform | 29.66M | -7.04 | ― | ― | ― | 95.87% | |
33 Underperform | 13.45M | -1.10 | ― | ― | ― | 47.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On March 4, 2025, CalciMedica announced new data from a post-hoc analysis of the Phase 2 CARDEA trial, highlighting Auxora’s potential in reducing mortality among patients with severe COVID-19 pneumonia and acute kidney injury (AKI). The analysis revealed a 62.7% relative reduction in mortality for Auxora-treated patients compared to placebo, indicating a significant therapeutic benefit. This data underscores the potential of CRAC channel inhibition in treating AKI and supports ongoing clinical trials, which may enhance CalciMedica’s positioning in the biopharmaceutical industry.